Literature DB >> 20357058

Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.

R Zichel1, A Mimran, A Keren, A Barnea, I Steinberger-Levy, D Marcus, A Turgeman, S Reuveny.   

Abstract

Botulinum toxins produced by the anaerobic bacterium Clostridium botulinum are the most potent biological toxins in nature. Traditionally, people at risk are immunized with a formaldehyde-inactivated toxin complex. Second generation vaccines are based on the recombinant carboxy-terminal heavy-chain (Hc) fragment of the neurotoxin. However, the materialization of this approach is challenging, mainly due to the high AT content of clostridial genes. Herein, we present an alternative strategy in which the native genes encoding Hc proteins of botulinum toxins A, B, and E were used to express the recombinant Hc fragments in a cell-free expression system. We used the unique property of this open system to introduce different combinations of chaperone systems, protein disulfide isomerase (PDI), and reducing/oxidizing environments directly to the expression reaction. Optimized expression conditions led to increased production of soluble Hc protein, which was successfully scaled up using a continuous exchange (CE) cell-free system. Hc proteins were produced at a concentration of more than 1 mg/ml and purified by one-step Ni(+) affinity chromatography. Mice immunized with three injections containing 5 microg of any of the in vitro-expressed, alum-absorbed, Hc vaccines generated a serum enzyme-linked immunosorbent assay (ELISA) titer of 10(5) against the native toxin complex, which enabled protection against a high-dose toxin challenge (10(3) to 10(6) mouse 50% lethal dose [MsLD(50)]). Finally, immunization with a trivalent HcA, HcB, and HcE vaccine protected mice against the corresponding trivalent 10(5) MsLD(50) toxin challenge. Our results together with the latest developments in scalability of the in vitro protein expression systems offer alternative routes for the preparation of botulinum vaccine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20357058      PMCID: PMC2863383          DOI: 10.1128/CVI.00496-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  54 in total

1.  A highly efficient and robust cell-free protein synthesis system prepared from wheat embryos: plants apparently contain a suicide system directed at ribosomes.

Authors:  K Madin; T Sawasaki; T Ogasawara; Y Endo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  Expression-independent consumption of substrates in cell-free expression system from Escherichia coli.

Authors:  R G Kim; C Y Choi
Journal:  J Biotechnol       Date:  2001-11-17       Impact factor: 3.307

3.  Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin.

Authors:  J L Holley; M Elmore; M Mauchline; N Minton; R W Titball
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

4.  Expression of Fab fragment of catalytic antibody 6D9 in an Escherichia coli in vitro coupled transcription/translation system.

Authors:  XiuPing Jiang; Yuji Ookubo; Ikuo Fujii; Hideo Nakano; Tsuneo Yamane
Journal:  FEBS Lett       Date:  2002-03-13       Impact factor: 4.124

5.  Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia.

Authors:  Hideyuki Arimitsu; Kaoru Inoue; Yoshihiko Sakaguchi; Jaechul Lee; Yukako Fujinaga; Toshihiro Watanabe; Tohru Ohyama; Robert Hirst; Keiji Oguma
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

6.  A cell-free protein synthesis system for high-throughput proteomics.

Authors:  Tatsuya Sawasaki; Tomio Ogasawara; Ryo Morishita; Yaeta Endo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-30       Impact factor: 11.205

7.  Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris.

Authors:  M P Byrne; R W Titball; J Holley; L A Smith
Journal:  Protein Expr Purif       Date:  2000-04       Impact factor: 1.650

Review 8.  Botulinum toxin as a biological weapon: medical and public health management.

Authors:  S S Arnon; R Schechter; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; J Hauer; M Layton; S Lillibridge; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; D L Swerdlow; K Tonat
Journal:  JAMA       Date:  2001-02-28       Impact factor: 56.272

Review 9.  Development of vaccines for prevention of botulism.

Authors:  M P Byrne; L A Smith
Journal:  Biochimie       Date:  2000 Sep-Oct       Impact factor: 4.079

10.  A long-lived batch reaction system of cell-free protein synthesis.

Authors:  Y Kawarasaki; T Kawai; H Nakano; T Yamane
Journal:  Anal Biochem       Date:  1995-04-10       Impact factor: 3.365

View more
  28 in total

1.  Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Authors:  James S Henkel; William H Tepp; Amanda Przedpelski; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

Review 2.  Cell-free protein synthesis: applications come of age.

Authors:  Erik D Carlson; Rui Gan; C Eric Hodgman; Michael C Jewett
Journal:  Biotechnol Adv       Date:  2011-10-08       Impact factor: 14.227

3.  DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge.

Authors:  Veronica L Scott; Daniel O Villarreal; Natalie A Hutnick; Jewell N Walters; Edwin Ragwan; Khalil Bdeir; Jian Yan; Niranjan Y Sardesai; Adam C Finnefrock; Danilo R Casimiro; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Oral vaccination with an adenovirus-vectored vaccine protects against botulism.

Authors:  Shan Chen; Qingfu Xu; Mingtao Zeng
Journal:  Vaccine       Date:  2013-01-04       Impact factor: 3.641

Review 5.  Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.

Authors:  Isabelle Legastelois; Sophie Buffin; Isabelle Peubez; Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

6.  DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: examples of the botulinum toxins types A, B, and E.

Authors:  Aurore Burgain; Alice Rochard; Capucine Trollet; Christelle Mazuet; Michel R Popoff; Virginie Escriou; Daniel Scherman; Pascal Bigey
Journal:  Hum Vaccin Immunother       Date:  2013-07-22       Impact factor: 3.452

7.  The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Authors:  Alon Ben David; Eran Diamant; Ada Barnea; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

8.  Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine.

Authors:  Maryam Amidi; Markus de Raad; Daan J A Crommelin; Wim E Hennink; Enrico Mastrobattista
Journal:  Syst Synth Biol       Date:  2010-10-26

Review 9.  Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs.

Authors:  Eran Diamant; Amram Torgeman; Eyal Ozeri; Ran Zichel
Journal:  Toxins (Basel)       Date:  2015-05-29       Impact factor: 4.546

10.  Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations.

Authors:  Eran Diamant; Bat-El Lachmi; Adi Keren; Ada Barnea; Hadar Marcus; Shoshana Cohen; Alon Ben David; Ran Zichel
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.